VANCOUVER, BC and MENLO PARK, CA–(Marketwired – Jun 26, 2013) -
DelMar Pharmaceuticals, Inc. (
OTCQB
:
DMPI
) announced today that Jeffrey
Bacha, president and CEO, will present at the 2013 OneMedForumNY
Emerging Company Finance Conference on Thursday, June 27, 2013 in
New York City at the Metropolitan Club.
The Company’s presentation is scheduled to begin at 10:00 a.m.
EDT. A webcast of the company’s presentation will be made
available via the conference website.
DelMar Pharmaceuticals 2013 Highlights:
June:Presented encouraging data from ongoing Phase
I/II glioblastoma multiforme (GBM) clinical trial with VAL-083 at
the American Society of Clinical Oncology (ASCO) Annual
Meeting
April: Clinical data presentation at the
American Association of Cancer Research (AACR) Annual Meeting
March:Named to Rocket Builders’ 2013 “Ready to
Rocket” list
March:Announced completion of $10.5 million
oversubscribed offering
February:Appointment John K. Bell, chairman of
Onbelay Capital Inc., to board of directors
January:Completed $5.4 million first closing and
public listing transaction
January:Received European orphan drug designation
for VAL-083 for the treatment of glioma
For more information and registration, please visit the
conference website:
http://www.onemedplace.com/forum/
About DelMar Pharma
DelMar Pharmaceuticals was founded in 2010 to develop and
commercialize proven cancer therapies in new orphan drug
indications where patients are failing modern targeted or biologic
treatments. The Company’s lead asset, VAL-083, is currently
undergoing clinical trials in the United States as a potential
treatment for refractory glioblastoma multiforme (GBM), the most
common and aggressive form of brain cancer. VAL-083 benefits
from extensive clinical research sponsored by the US National
Cancer Institute, and is currently approved for the treatment of
chronic myelogenous leukemia (CML) and lung cancer in China.
Published pre-clinical and clinical data suggest that VAL-083 may
be active against a range of tumor types via a novel mechanism of
action.
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements contained herein are
based on current expectations, but are subject to a number of risks
and uncertainties. The factors that could cause actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to the
Company’s ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the Company’s
products and technology; the availability of substantial additional
funding for the Company to continue its operations and to conduct
research and development, clinical studies and future product
commercialization; and, the Company’s business, research, product
development, regulatory approval, marketing and distribution plans
and strategies. These and other factors are identified and
described in more detail in our filings with the SEC, including,
our current reports on Form 8-K. We do not undertake to update
these forward-looking statements made by us.
For further information, please visit
www.delmarpharma.com
;or contact
Jeffrey A. Bacha, President & CEO (604)
629-5989or
Booke & Company Investor Relations,
admin@bookeandco.com
Jeffrey A. Bacha
President & CEO
(604) 629-5989
Booke & Company Investor Relations
admin@bookeandco.com